Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
PDA J Pharm Sci Technol ; 55(4): 230-4, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11505555

RESUMO

According to the FDA guidelines (1), pilot plant facilities may be used to generate material to support process validation studies. The guidelines also state that process modifications are an inevitable part of process development and scale-up. However, if such modifications are made, there is a need to demonstrate that the products from both the old and new processes are comparable (2). Both of these guidelines were combined and applied during a recent development of a product at Genentech. In order to implement the process modifications and demonstrate product comparability, the pilot plant facilities were used for these production runs. As the process had changed and the product was being prepared for BLA submission, in process samples from the new manufacturing process were also required to support the process validation studies. By using pilot plant facilities to implement the process modifications, test product comparability, and produce material for process validation, we were able to minimize the impact of such work on the large-scale manufacturing facility.


Assuntos
Indústria Farmacêutica/normas , Tecnologia Farmacêutica , Guias como Assunto , Projetos Piloto , Reprodutibilidade dos Testes
2.
Cardiovasc Res ; 51(2): 265-74, 2001 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-11470466

RESUMO

OBJECTIVE: The cytokine cardiotrophin-1 (CT-1) has previously been shown to protect cultured cardiocytes from cell death induced by serum removal or hypoxia when administered prior to the damaging stimulus. We wished to test whether a similar protective effect could be observed if CT-1 was added after the ischaemic period and to investigate the signalling pathways involved in the protective effect when CT-1 is given prior to or after ischaemia. METHODS: We therefore examined the protective effect of CT-1 in cultured rat cardiocytes exposed to simulated ischaemia followed by reoxygenation when CT-1 was administered either prior to simulated ischaemia or at reoxygenation. RESULTS: We show that CT-1 can exert a protective effect against the damaging effects of simulated ischaemia/reoxygenation both when added after the simulated ischaemia at reoxygenation (P<0.05 in trypan blue, TUNEL and annexin V assays) or when added prior to the simulated ischaemia (P<0.05). In both cases, these protective effects are blocked by an inhibitor of the p42/p44 MAPK pathway (P<0.05 in all assays). CONCLUSION: CT-1 can protect cardiac cells when added either prior to simulated ischaemia or at the time of reoxygenation following simulated ischaemia and these effects are dependent upon its ability to activate the p42/p44 MAPK pathway. Hence CT-1 may have therapeutic potential when added at the time of reperfusion following ischaemic damage.


Assuntos
Citocinas/uso terapêutico , Sistema de Sinalização das MAP Quinases/fisiologia , Traumatismo por Reperfusão Miocárdica/prevenção & controle , Miocárdio/metabolismo , Animais , Anexina A5/análise , Apoptose/efeitos dos fármacos , Células Cultivadas , Proteínas de Ligação a DNA/metabolismo , Ativação Enzimática , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Proteína Quinase 1 Ativada por Mitógeno/metabolismo , Proteína Quinase 3 Ativada por Mitógeno , Proteínas Quinases Ativadas por Mitógeno/metabolismo , Traumatismo por Reperfusão Miocárdica/patologia , Ratos , Ratos Sprague-Dawley , Fator de Transcrição STAT3 , Transativadores/metabolismo
3.
Muscle Nerve ; 24(6): 769-77, 2001 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-11360260

RESUMO

Cardiotrophin-1 (CT-1) has potent survival-promoting effects on motor neurons in vitro and in vivo and may be effective in treating motor neuron diseases (MND). We investigated the effects of CT-1 treatment in wobbler mouse MND. Wobbler mice were randomly assigned to receive subcutaneously injected CT-1 (1 mg/kg, n = 18, in two experiments) or vehicle (n = 18, in two experiments) daily, 6 times/week for 4 weeks after clinical diagnosis at age 3 to 4 weeks. Cardiotrophin-1 treatment prevented deterioration in paw position and walking pattern abnormalities. Grip strength declined steadily in the vehicle group, whereas in the CT-1 group it declined at week 1 but increased thereafter to exceed baseline strength by 5% (P = 0.0002) at week 4. Running speed was faster with CT-1 (P = 0.007). Biceps muscle twitch tension, muscle weight, mean muscle fiber diameter, and intramuscular axonal sprouting were significantly greater with CT-1 treatment than with vehicle treatment. Histometry revealed a trend that indicated CT-1 modestly increased the number of immunoreactive motor neurons, as determined by both choline acetyltransferase and c-Ret antibodies, and reduced the number of phosphorylated neurofilament immunoreactive perikarya (P = 0.05). The number of large myelinated motor axons significantly increased with treatment (206 versus 113, P = 0.01). We conclude that CT-1 exerts myotrophic effects as well as neurotrophic effects in a mouse model of spontaneous MND, a finding that has potential therapeutic implications for human MND.


Assuntos
Citocinas/uso terapêutico , Doença dos Neurônios Motores/tratamento farmacológico , Animais , Citocinas/administração & dosagem , Progressão da Doença , Marcha/efeitos dos fármacos , Injeções Subcutâneas , Camundongos , Camundongos Mutantes Neurológicos , Atividade Motora/efeitos dos fármacos , Doença dos Neurônios Motores/patologia , Doença dos Neurônios Motores/fisiopatologia , Contração Muscular/efeitos dos fármacos , Fibras Musculares Esqueléticas/efeitos dos fármacos , Fibras Musculares Esqueléticas/patologia , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/patologia , Músculo Esquelético/fisiopatologia , Tamanho do Órgão/efeitos dos fármacos , Corrida , Fatores de Tempo
4.
J Neurochem ; 74(2): 582-95, 2000 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-10646509

RESUMO

Neurotrophic factors (NTFs) can protect against or sensitize neurons to excitotoxicity. We studied the role played by various NTFs in the excitotoxic death of purified embryonic rat motor neurons. Motor neurons cultured in brain-derived neurotrophic factor, but not neurotrophin 3, glial-derived neurotrophic factor, or cardiotrophin 1, were sensitive to excitotoxic insult. BDNF also induces excitotoxic sensitivity (ES) in motor neurons when BDNF is combined with these other NTFs. The effect of BDNF depends on de novo protein and mRNA synthesis. Reagents that either activate or inhibit the 75-kDa NTF receptor p75NTR do not affect BDNF-induced ES. The low EC50 for BDNF-induced survival and ES suggests that TrkB mediates both of these biological activities. BDNF does not alter glutamate-evoked rises of intracellular Ca2+, suggesting BDNF acts downstream. Both wortmannin and LY294002, which specifically block the phosphatidylinositol 3-kinase (PI3K) intracellular signaling pathway in motor neurons, inhibit BDNF-induced ES. We confirm this finding using a herpes simplex virus (HSV) that expresses the dominant negative p85 subunit of PI3K. Infecting motor neurons with this HSV, but not a control HSV, blocks activation of the PI3K pathway and BDNF-induced ES. Through the activation of TrkB and the PI3K signaling pathway, BDNF renders developing motor neurons susceptible to glutamate receptor-mediated cell death.


Assuntos
Fator Neurotrófico Derivado do Encéfalo/farmacologia , Neurônios Motores/efeitos dos fármacos , Neurotoxinas/farmacologia , Fosfatidilinositol 3-Quinases/metabolismo , Medula Espinal/efeitos dos fármacos , Medula Espinal/enzimologia , Animais , Cálcio/metabolismo , Células Cultivadas , Sinergismo Farmacológico , Ativação Enzimática/fisiologia , Ácido Glutâmico/farmacologia , Neurônios Motores/enzimologia , Neurônios Motores/metabolismo , Biossíntese de Proteínas , RNA Mensageiro/biossíntese , Ratos , Ratos Sprague-Dawley , Receptor de Fator de Crescimento Neural/fisiologia , Receptor trkB/fisiologia , Medula Espinal/citologia , Medula Espinal/metabolismo
5.
J Surg Res ; 84(2): 240-6, 1999 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-10357926

RESUMO

Cardiotrophin-1 (CT-1) is a recently discovered member of the gp130 cytokine family, which includes IL-6, IL-11, leukemia inhibitory factor, ciliary neurotrophic factor, and oncostatin M. Recent evidence suggests that, like other members of this family, CT-1 may possess anti-inflammatory properties. We hypothesized that in vivo CT-1 administration would attenuate endotoxin (ETX)-induced acute lung injury. We studied the effects of CT-1 (100 microgram/kg ip, 10 min prior to ETX) in a rat model of ETX-induced acute lung injury (Salmonella typhimurium lipopolysaccharide, 20 mg/kg ip). Six hours after ETX, lungs were harvested for determination of neutrophil accumulation (myeloperoxidase, MPO, assay) and lung edema (wet-to-dry weight ratio). Mechanisms of pulmonary vasorelaxation were examined in isolated pulmonary artery rings at 6 h by interrogating endothelium-dependent (response to acetylcholine) and endothelium-independent (response to sodium nitroprusside) relaxation following alpha-adrenergic (phenylephrine)-stimulated preconstriction. CT-1 abrogated the endotoxin-induced lung neutrophil accumulation: 2.3 +/- 0.2 units MPO/g wet lung (gwl) vs 6. 3 +/- 0.3 units MPO/gwl in the ETX group (P < 0.05 vs ETX, P > 0.05 vs control). Similarly, CT-1 prevented ETX-induced lung edema: wet-to-dry-weight ratio, 4.473 +/- 0.039 vs 4.747 +/- 0.039 in the ETX group (P < 0.05 vs ETX, P > 0.05 vs control). Endotoxin caused significant impairment of both endothelium-dependent and -independent pulmonary vasorelaxation, and CT-1 attenuated this injury. Thus, cardiotrophin-1 possesses significant anti-inflammatory properties in a model of endotoxin-induced acute lung injury.


Assuntos
Citocinas/farmacologia , Edema/induzido quimicamente , Edema/prevenção & controle , Endotoxinas , Pneumopatias/induzido quimicamente , Pneumopatias/prevenção & controle , Doença Aguda , Animais , GMP Cíclico/fisiologia , Endotoxemia/patologia , Pulmão/patologia , Pneumopatias/patologia , Pneumopatias/fisiopatologia , Masculino , Neutrófilos/patologia , Circulação Pulmonar/efeitos dos fármacos , Circulação Pulmonar/fisiologia , Ratos , Ratos Sprague-Dawley , Vasodilatação/efeitos dos fármacos , Vasodilatação/fisiologia
6.
Anal Biochem ; 250(1): 1-9, 1997 Jul 15.
Artigo em Inglês | MEDLINE | ID: mdl-9234892

RESUMO

Two fluorimetric assays for the determination of pyroglutamyl aminopeptidase type-II activity have been developed. The assays are based on hydrolysis of the quenched-fluorimetric substrate

Assuntos
Aminopeptidases/metabolismo , Animais , Bovinos , Cumarínicos/análise , Cumarínicos/metabolismo , Ciclização , Dipeptidil Peptidase 4/metabolismo , Oligopeptídeos/metabolismo , Ácido Pirrolidonocarboxílico/análogos & derivados , Espectrometria de Fluorescência
7.
Int J Biochem Cell Biol ; 28(4): 441-9, 1996 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-9026355

RESUMO

Prolyl endopeptidase has been predominantly described as a cytosolic activity capable of cleaving a number of important neuropeptides (including TRH, LHRH, Bradykinin, Angiotensin, Substance P, Neurotensin, Oxytocin and Vasopressin) on the carboxy side of proline. In this paper, we report, for the first time, on the complete purification and characterization of a membrane-bound form of prolyl endopeptidase. This novel activity has been isolated from the synaptosomal (plasma membranes) membranes of bovine brain. Following gel filtration, hydroxylapatite and hydrophobic interaction chromatographies, the prolyl endopeptidase activity was purified 1400-fold with a 23% recovery of activity. The enzyme was shown to have a relative molecular mass of 87 kDa and a Km of 60 microM for its specific fluorimetric substrate, Z-GlyProMCA. The purified enzyme demonstrated a relatively broad substrate specificity and a relatively high affinity for proline-containing neuropeptides. It was shown to be inhibited by certain thiol-protease inhibitors and by the metal chelator, 1,10-phenanthroline, thus possibly classifying it as a 'thimet' activity. The purified particular form of proyl endopeptidase displayed a similar substrate specificity to the previously reported cytosolic forms of the enzyme. However, there were differences between the two forms in term of their sensitivity to inhibitors, their affinities for the peptide substrates and their relative molecular masses. The different subcellular location (i.e. the synaptosomal membrane) of the particulate prolyl endopeptidase is also of potential physiological significance given that here it is more likely to come in contact with the vesicle-bound neuropeptides than is its cytosolic counterpart.


Assuntos
Encéfalo/enzimologia , Serina Endopeptidases/isolamento & purificação , Sinaptossomos/enzimologia , Animais , Encéfalo/efeitos dos fármacos , Encéfalo/ultraestrutura , Bovinos , Membrana Celular/efeitos dos fármacos , Membrana Celular/enzimologia , Inibidores Enzimáticos/farmacologia , Prolil Oligopeptidases , Especificidade por Substrato , Sinaptossomos/efeitos dos fármacos
8.
Int J Biochem Cell Biol ; 27(9): 881-90, 1995 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-7584623

RESUMO

Pyroglutamate aminopeptidase type II is a highly specific membrane-bound neuropeptidase that has the ability to remove N-terminal pyroglutamate (Glp) from Thyrotropin Releasing Hormone (Glp-His-Pro-NH2) or very closely related tripeptides or tripeptide amides. In this paper we report on the purification and characterisation of a pyroglutamate aminopeptidase activity from the synaptosomal membranes of bovine brain. The Triton X-100 solubilised enzyme was purified nearly 600-fold by a combination of conventional column chromatography steps with a recovery/yield of 17.0%. Phase-partitioning experiments with Triton X-114 showed the activity to be an integral membrane protein. This detergent-solubilised pyroglutamate aminopeptidase activity was found to have a relative molecular mass of 240 kDa on a calibrated S-200 column. HPLC analysis on a C18 reverse-phase column showed that the purified activity displayed a very narrow substrate specificity cleaving only Thyrotropin Releasing Hormone (TRH) or the very closely related acid-TRH, LHRH (1-3) and the TRH-analogue (methyl-His)-TRH and had a Km of 100 microM for the fluorimetric substrate Glp-His-Pro-methyl-coumarin. The enzyme was inactivated by the metalchelator 1,10-ortho-phenanthroline but showed less sensitivity to EDTA. It also showed some inhibition by thiol protease inhibitors such as iodoacetate and n-ethyl-maleimide. In summary, we have purified a pyroglutamate aminopeptidase from the synaptosomal membrane of bovine brain. This enzyme displays characteristics consistent with it being classified as a PAP type II neuropeptidase with only minor differences from other proteases in this group.


Assuntos
Encéfalo/metabolismo , Piroglutamil-Peptidase I/metabolismo , Sinaptossomos/enzimologia , Hormônio Liberador de Tireotropina/metabolismo , Sequência de Aminoácidos , Animais , Encéfalo/enzimologia , Bovinos , Dados de Sequência Molecular , Piroglutamil-Peptidase I/antagonistas & inibidores , Piroglutamil-Peptidase I/classificação , Piroglutamil-Peptidase I/isolamento & purificação , Membranas Sinápticas/enzimologia
9.
Eur J Biochem ; 227(1-2): 277-83, 1995 Jan 15.
Artigo em Inglês | MEDLINE | ID: mdl-7851396

RESUMO

Prolyl endopeptidase, which has long been recognised for its importance in the degradation of several neuropeptides such as thyroliberin, luteinising hormone releasing hormone, angiotensin, substance P and neurotensin, has been widely characterised as a cytosolic enzyme. However, in this paper, we report the presence of a prolyl endopeptidase activity in the particulate fractions of bovine brain, which is distinct from that in the cytoplasm. This previously uncharacterised activity was found to reside in the synaptosomal membranes, a location which is highly significant for the inactivation of neuropeptides in brain. Following vigorous salt washing and osmotic shock, the prolyl endopeptidase activity was released from the membranes by treatment with the detergent Triton X-100, and was partially purified by gel filtration on a Sephacryl S-200HR column. This prolyl endopeptidase activity was shown to have a molecular mass (87 kDa) higher than the cytosolic prolyl endopeptidase but, from initial investigation, appears to demonstrate a similarly broad substrate specificity towards proline-containing neuropeptides. The partially purified enzyme was inhibited by certain thiol-protease inhibitors and was also found to be sensitive to the metal chelator 1,10-phenanthroline.


Assuntos
Encéfalo/enzimologia , Serina Endopeptidases/metabolismo , Sinaptossomos/enzimologia , Animais , Bovinos , Cromatografia em Gel , Cromatografia Líquida de Alta Pressão , Indicadores e Reagentes , Membranas Intracelulares/enzimologia , Prolil Oligopeptidases , Sais , Serina Endopeptidases/isolamento & purificação , Inibidores de Serina Proteinase/farmacologia , Frações Subcelulares/enzimologia , Especificidade por Substrato , Hormônio Liberador de Tireotropina/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA